Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03670030
What this trial is testing

TestABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Who this might be right for
Neuroendocrine Tumors
Robert Ramirez 5
Testing effectiveness (Phase 2)WithdrawnNCT05582031
What this trial is testing

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Who this might be right for
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more
Translational Research in Oncology
Testing effectiveness (Phase 2)UnknownNCT02687958
What this trial is testing

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Who this might be right for
Neuroendocrine Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica 30
Not applicableStudy completedNCT02948946
What this trial is testing

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm
H. Lee Moffitt Cancer Center and Research Institute 105
Not applicableActive Not RecruitingNCT05064150
What this trial is testing

Neuroendocrine Tumors - Patient Reported Outcomes

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm+1 more
University of Iowa 2,539
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Testing effectiveness (Phase 2)WithdrawnNCT03901378
What this trial is testing

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungHigh Grade Neuroendocrine Carcinoma, Any Site
Ochsner Health System
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Testing effectiveness (Phase 2)Ended earlyNCT05987176
What this trial is testing

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Who this might be right for
Neuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine Tumors+3 more
Imperial College London 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Large-scale testing (Phase 3)Study completedNCT00690430
What this trial is testing

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Who this might be right for
Symptomatic Refractory Resistant Carcinoid Disease
Novartis Pharmaceuticals 186
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Very early researchUnknownNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Large-scale testing (Phase 3)Looking for participantsNCT07185672
What this trial is testing

PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Neuroendocrine Tumor GEP Grade 1-3Neuroendocrine Gastroenteropancreatic Tumour
Tata Memorial Hospital 162
Large-scale testing (Phase 3)Study completedNCT01842165
What this trial is testing

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Jules Bordet Institute 37
Testing effectiveness (Phase 2)Study completedNCT02231762
What this trial is testing

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 57
Testing effectiveness (Phase 2)Looking for participantsNCT07278479
What this trial is testing

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Who this might be right for
Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more
Molecular Partners AG 138
Large-scale testing (Phase 3)Study completedNCT02608203
What this trial is testing

[68 Ga]-DOTANOC PET/CT in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Assistance Publique Hopitaux De Marseille 18
Not applicableLooking for participantsNCT04090034
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System 50
Not applicableWithdrawnNCT03895463
What this trial is testing

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

Who this might be right for
Neuroendocrine Tumors
Ipsen
Next Page